Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.
Zyme Biotech a leading provider of strategic solutions for the biopharmaceutical and life sciences industries proudly announces a groundbreaking partnership with ValGenesis EMEA BV a subsidiary of ValGenesis Inc
Dr Reddys Laboratories Ltd announced the launch of Toripalimab in India Toripalimab is a New Biological Entity NBE It is the only immunooncology drug approved by various regulatory authorities around the world such as the United States Food and Drug...
Allink Biotherapeutics a clinicalstage biotechnology company pioneering nextgeneration bispecific antibody and antibodydrug conjugate ADC therapeutics today announced the successful completion of a million Series A financing
Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of oncology cardiovascular and metabolic autoimmune
Zai Lab Limitedtoday announced that the National Reimbursement Drug List NRDL released by Chinas National Healthcare Security Administration NHSA has been updated to include the following medicines and indications
Sichuan KelunBiotech Biopharmaceutical Co Ltdannounced that the Company received marketing authorization in China from National Medical Products Administration NMPA for the first domestically developed trophoblast cellsurface antigen
Satsuma Pharmaceuticals Inc a latestage biopharmaceutical company and its corporate parent Shin Nippon Biomedical Laboratories Ltd are pleased to announce that the US Food and Drug Administration FDA
MaxScientific Inc today announced that it has entered into a strategic licensing agreement with Seragon Biosciences Inc marking a collaboration between the two leaders in the field of aging and longevity intervention technologies Under this agreement...
Arrowhead Pharmaceuticals Inctoday announced a global licensing and collaboration agreement with Sarepta Therapeutics NASDAQ SRPT Upon closing Arrowhead will receive million consisting of million cash and million as an equity investment priced at...
Monument Therapeutics a precision neuroscience company today announced the first participant has been successfully dosed in its Phase I clinical study of MT a novel treatment targeting cognitive impairment associated with schizophrenia CIAS